background
apic
membran
antigen
one
beststudi
bloodstag
malaria
vaccin
candid
vaccin
test
malaria
popul
induc
function
activ
antibodi
judg
growth
inhibit
assay
gia
howev
vaccin
fail
induc
higher
growthinhibitori
activ
adult
live
malaria
endem
area
vaccin
induc
function
activ
antibodi
malariaexpos
children
less
inhibit
gia
baselin
children
level
baselin
inhibit
method
total
igg
purifi
plasma
collect
pediatr
trial
immun
pool
total
igg
made
anoth
set
total
igg
purifi
us
adult
immun
ustot
igg
total
igg
igg
affin
purifi
function
activ
igg
evalu
gia
competit
elisa
perform
ustot
igg
igg
malariaexpos
children
result
igg
malariaexpos
children
us
vaccine
show
similar
growthinhibitori
activ
concentr
mix
ustot
igg
igg
children
show
interfer
effect
gia
interestingli
interfer
effect
higher
igg
higher
titer
pool
igg
compet
antibodi
ustot
igg
competit
elisa
conclus
children
live
malaria
endem
area
fraction
igg
interfer
biolog
activ
antibodi
judg
gia
mechan
interfer
resolv
studi
result
suggest
caus
direct
competit
igg
protein
studi
indic
antimalaria
igg
induc
natur
exposur
may
interfer
biolog
effect
antibodi
induc
vaccin
target
popul
estim
million
malaria
case
million
death
vast
major
death
occur
african
children
less
old
due
plasmodium
falciparum
virul
speci
human
malaria
protect
mechan
remain
elucid
passiv
transfer
studi
shown
import
gammaglobulin
bloodstag
p
falciparum
control
eventu
erad
malaria
effect
vaccin
consid
need
addit
exist
tool
drug
insecticid
etc
apic
membran
antigen
one
beststudi
bloodstag
vaccin
candid
essenti
protein
parasit
invas
erythrocyt
invas
process
complic
ie
initi
attach
reorient
tight
junction
format
intern
differ
studi
suggest
differ
role
bind
erythrocyt
reorient
intern
addit
erythrocyt
invas
recent
studi
suggest
involv
sporozoit
invas
hepatocyt
result
indic
protein
may
multipl
role
mani
studi
shown
vaccin
induc
protect
immun
anim
model
review
aotu
monkey
challeng
model
monkey
challeng
p
falciparum
monkey
challeng
model
antibodi
level
induc
vaccin
challeng
shown
correl
protect
addit
anim
data
mani
epidemiolog
studi
suggest
high
level
antibodi
associ
reduc
risk
malaria
base
find
multipl
phase
trial
phase
field
trial
conduct
publish
howev
date
signific
protect
effect
shown
target
popul
african
children
vitro
parasit
growth
inhibit
assay
gia
also
refer
invas
inhibit
assay
iia
one
widelyus
biolog
assay
measur
function
activ
antibodi
bloodstag
malaria
still
controversi
whether
activ
measur
gia
iia
reflect
protect
immun
induc
vaccin
assay
use
preclin
clinic
studi
one
immunolog
readout
antibodi
induc
malaria
infect
also
antibodi
induc
immun
malaria
individu
show
growthinhibitori
activ
vitro
gia
contrast
vaccin
increas
antibodi
level
administ
adult
live
malaria
endem
area
vaccin
chang
parasit
growthinhibitori
activ
previou
studi
purifi
total
igg
sera
collect
epidemiolog
studi
mali
major
sera
collect
adult
separ
igg
affin
chromatographi
fraction
igg
fraction
bind
igg
previous
shown
igg
specif
fraction
igg
bind
malaria
extract
reduc
function
activ
antibodi
us
vaccine
interfer
igg
induc
malaria
infect
like
explain
reason
vaccin
induc
higher
growthinhibitori
activ
malian
adult
vaccin
trial
limit
volum
sera
collect
children
epidemiolog
studi
could
investig
whether
interf
igg
children
main
target
popul
bloodstag
vaccin
less
previou
exposur
malaria
recent
phase
trial
malian
children
show
small
signific
increas
growthinhibitori
activ
data
children
analyz
gia
perform
total
igg
studi
level
increas
activ
differ
level
observ
us
adult
immun
vaccin
formul
us
vaccin
trial
volunt
show
neglig
level
inhibit
vaccin
immun
growthinhibitori
activ
total
igg
function
titer
howev
malian
children
increas
growthinhibitori
activ
observ
children
less
inhibit
vaccin
none
children
inhibit
vaccin
children
group
show
increas
antibodi
level
measur
elisa
increas
children
hand
remain
children
less
inhibit
vaccin
children
increas
vaccin
present
studi
wish
investig
effect
igg
children
determin
whether
similar
interfer
effect
could
identifi
therefor
made
multipl
pool
total
igg
separ
igg
test
gia
igg
show
interfer
effect
growthinhibitori
activ
detail
us
adult
phase
trial
phase
trial
malian
children
suppli
elsewher
brief
adult
year
age
enrol
us
trial
immun
day
mg
mixtur
recombin
protein
formul
alhydrogelh
mix
cpg
plasma
sampl
individu
high
level
antibodi
determin
elisa
day
collect
month
final
vaccin
mali
trial
malian
children
year
old
enrol
immun
day
either
mg
alhydrogelh
compar
vaccin
hiberixh
blood
sampl
collect
day
trial
conduct
investig
new
drug
applic
review
us
food
drug
administr
us
phase
trial
review
approv
institut
review
board
irb
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
univers
rochest
research
subject
review
board
written
inform
consent
obtain
volunt
mali
phase
trial
review
approv
irb
niaid
nih
ethic
committe
faculti
medicin
pharmaci
dentistri
univers
bamako
commun
consent
obtain
meet
villag
leader
head
famili
commun
member
prior
start
phase
studi
individu
inform
consent
obtain
oral
translat
consent
form
local
languag
understand
content
consent
confirm
mean
multipl
choic
questionnair
parent
guardian
unabl
read
place
imprint
hisher
finger
place
signatur
independ
wit
also
sign
consent
form
total
igg
prepar
total
igg
purifi
individu
plasma
sampl
us
trial
n
normal
us
sera
n
use
protein
g
column
describ
previous
similarli
total
igg
prepar
plasma
sampl
collect
day
mali
phase
trial
total
igg
dialyz
rpmi
concentr
mgml
volum
total
igg
individu
malian
child
enough
perform
igg
purif
total
igg
sampl
rank
base
antibodi
level
judg
elisa
divid
group
make
pool
igg
time
point
follow
day
igg
regardless
immun
group
day
igg
hiberixhvaccin
children
day
igg
children
number
individu
total
igg
use
make
total
igg
pool
antibodi
level
pool
shown
tabl
although
antimalari
antibodi
day
igg
day
igg
hiberix
group
induc
natur
infect
possibl
vaccin
hiberixh
andor
time
blood
collect
malaria
transmiss
season
might
alter
immun
respons
therefor
made
separ
pool
igg
day
igg
day
igg
hiberixh
group
studi
us
total
igg
mali
total
igg
pool
fvo
specif
igg
fvo
igg
prepar
individu
use
fvo
protein
immobil
sepharos
fast
flow
column
describ
previous
affin
purif
process
total
igg
flowthrough
fraction
reload
column
three
time
increas
efficaci
separ
igg
igg
dialyz
rpmi
concentr
ml
igg
mgml
igg
final
product
limit
volum
avail
igg
prepar
total
igg
pool
standard
methodolog
perform
elisa
describ
previous
absorb
test
sampl
convert
elisa
unit
use
standard
curv
gener
serial
dilut
standard
plate
elisa
unit
sampl
convert
mgml
use
convers
factor
describ
elsewher
minim
detect
level
antibodi
studi
mgml
respons
limit
detect
assign
valu
mgml
analysi
competit
elisa
fix
amount
total
igg
us
vaccine
design
ustot
igg
give
approxim
od
valu
approxim
mgml
total
igg
elisa
well
mix
dilut
igg
malian
children
rang
mgml
elisa
well
mixtur
test
elisa
use
fvo
coat
plate
use
standard
elisa
procedur
direct
od
valu
use
final
readout
instead
elisa
unit
standard
methodolog
gia
describ
previous
assay
perform
purifi
igg
indic
concentr
fvo
strain
p
falciparum
parasit
mixtur
gia
experi
mgml
fvo
igg
mix
ustot
igg
concentr
ustot
igg
determin
igg
expect
give
inhibit
final
mixtur
standard
gia
growthinhibitori
activ
mixtur
determin
use
standard
gia
correl
two
data
set
eg
antibodi
level
inhibit
gia
etc
test
spearman
rank
correl
test
bestfit
formul
gia
data
calcul
use
logarithmtransform
antibodi
level
evalu
interfer
effect
igg
delta
inhibit
calcul
follow
delta
inhibit
inhibit
ustot
igg
alon
inhibit
mixtur
igg
ustot
igg
data
analyz
use
prism
graphpad
softwar
inc
ca
usa
p
valu
less
consid
signific
began
affin
purif
igg
order
evalu
growthinhibitori
activ
fraction
assess
possibl
interf
antibodi
igg
malian
children
antibodi
level
total
igg
pool
fvo
igg
measur
elisa
result
shown
tabl
igg
less
antibodi
level
compar
correspond
origin
total
igg
pool
result
show
purif
method
use
studi
effici
investig
biolog
activ
igg
us
vaccine
malian
children
gia
figur
previou
studi
igg
us
vaccine
show
signific
correl
antibodi
level
percent
inhibit
test
homolog
strain
parasit
spearman
rank
correl
r
confid
interv
ci
r
ci
fvo
relationship
follow
symmetr
sigmoid
curv
antibodi
level
log
transform
r
fvo
igg
malian
children
show
almost
level
growthinhibitori
activ
level
antibodi
gia
well
regardless
pool
total
igg
test
data
igg
malian
children
combin
signific
correl
antibodi
level
elisa
percent
inhibit
gia
r
ci
fvo
r
ci
relationship
follow
symmetr
sigmoid
curv
r
fvo
result
indic
obviou
differ
biolog
activ
antibodi
among
igg
induc
vaccin
igg
us
vaccine
natur
infect
igg
pool
natur
infect
vaccin
igg
pool
next
evalu
activ
igg
malian
children
gia
two
differ
concentr
gia
well
use
homolog
strain
parasit
ie
igg
test
strain
parasit
fvo
igg
fvo
parasit
inhibit
igg
plot
origin
total
igg
pool
figur
slope
bestfit
line
ci
data
set
ci
fvo
sinc
slope
significantli
differ
show
deplet
igg
total
igg
materi
chang
growthinhibitori
activ
even
though
igg
total
igg
pool
also
show
activ
figur
assess
interfer
effect
igg
igg
test
gia
either
presenc
total
igg
us
vaccine
ustot
igg
homolog
strain
parasit
ie
igg
test
without
ustot
igg
use
strain
parasit
gia
fvo
igg
similarli
test
use
fvo
parasit
ustot
igg
also
test
alon
posit
control
black
bar
figur
igg
show
less
inhibit
mgml
figur
mixtur
igg
ustot
igg
display
lower
inhibit
fvo
parasit
compar
ustot
igg
alon
evalu
strength
interfer
effect
igg
differ
ustot
igg
alon
mixtur
calcul
delta
inhibit
shown
figur
igg
purifi
total
igg
pool
higher
antibodi
level
show
greater
interfer
larger
delta
inhibit
total
igg
pool
lower
titer
data
combin
signific
correl
antibodi
level
origin
total
igg
pool
interfer
effect
igg
spearman
rank
correl
p
r
p
r
fvo
test
whether
interf
effect
igg
due
block
bind
antigen
antibodi
competit
elisa
perform
fix
amount
ustot
igg
mix
serial
dilut
igg
show
higher
interfer
effect
figur
ie
mixtur
appli
fvo
coat
elisa
plate
primari
antibodi
amount
antibodi
bound
protein
measur
mixtur
mgml
igg
elisa
use
coat
plate
ratio
ustot
igg
igg
test
figur
gia
use
strain
parasit
mgml
fvo
igg
fvo
shown
figur
none
igg
test
block
bind
antibodi
ustot
igg
elisa
plate
assay
conduct
use
total
igg
anoth
us
vaccine
also
show
competit
data
shown
thu
appear
interf
effect
due
direct
inhibit
antibodi
bind
plate
antigen
present
studi
shown
igg
malian
children
interfer
growthinhibitori
activ
antibodi
obtain
malaria
us
volunt
vaccin
ustot
igg
interestingli
interfer
effect
igg
total
igg
pool
higher
titer
higher
total
igg
pool
lower
titer
howev
igg
show
interfer
gia
block
bind
antibodi
ustot
igg
protein
competit
elisa
case
virus
hepat
c
viru
hcv
human
immunodefici
viru
hiv
studi
show
either
monoclon
polyclon
antibodi
interfer
effect
monoclon
polyclon
antibodi
neutral
assay
studi
antibodi
recogn
differ
epitop
antigen
mechan
interfer
may
explain
steric
block
andor
conform
rearrang
induc
nonneutr
antibodi
similar
phenomenon
report
p
falciparum
merozoit
surfac
protein
anoth
bloodstag
vaccin
candid
case
proport
antibodi
call
block
antibodi
found
peopl
live
malaria
endem
area
compet
monoclon
antibodi
capabl
inhibit
merozoit
invas
erythrocyt
vitro
judg
competit
elisa
process
assay
howev
clear
whether
block
antibodi
interfer
activ
antibodi
especi
activ
polyclon
antibodi
biolog
assay
gia
report
human
block
antibodi
interfer
invasioninhibitori
activ
mous
monoclon
antibodi
mab
human
antibodi
block
biolog
activ
anoth
inhibitori
mab
knowledg
igg
report
antibodi
shown
interfer
growthinhibitori
activ
induc
human
antigenspecif
polyclon
antibodi
howev
conceiv
similar
function
interfer
effect
exist
antibodi
malari
antigen
includ
contrast
case
hcv
hiv
igg
test
studi
show
neglig
level
bind
protein
judg
elisa
tabl
addit
igg
compet
ustot
igg
competit
elisa
figur
test
time
greater
ratio
igg
ustot
igg
compar
ratio
test
gia
figur
igg
show
interfer
effect
still
competit
observ
sinc
igg
residu
antibodi
final
prepar
one
may
consid
possibl
residu
antibodi
igg
mask
competit
effect
howev
think
case
igg
test
mgml
gave
ratio
igg
ustot
igg
test
figur
amount
antibodi
come
igg
less
compar
one
ustot
igg
even
highest
concentr
igg
test
ie
mgml
antibodi
igg
less
compar
one
ustot
igg
therefor
conclud
competit
effect
obviou
result
suggest
either
bind
protein
igg
weak
detect
convent
elisa
andor
mechan
interfer
igg
indirect
effect
function
invas
process
also
mechan
invas
inhibit
antibodi
still
controversi
studi
show
rabbit
polyclon
growthinhibitori
antibodi
disrupt
proteolyt
process
studi
inhibitori
mab
peptid
show
block
complex
format
rhoptri
neck
protein
previou
studi
shown
interf
activ
due
malariaspecif
igg
igg
popul
howev
growthinhibitori
activ
igg
previou
studi
high
igg
collect
mainli
malian
adult
could
nt
measur
strength
interfer
effect
studi
igg
malian
children
could
perform
malariaextractspecif
igg
purif
igg
limit
quantiti
blood
sampl
avail
hand
intrins
growthinhibitori
activ
igg
figur
correl
antibodi
level
origin
total
igg
pool
interfer
effect
correspond
igg
fvo
b
antibodi
level
mgml
origin
total
igg
pool
xaxi
plot
delta
inhibit
igg
yaxi
test
p
falciparum
fvo
b
parasit
delta
inhibit
igg
calcul
use
data
present
figur
follow
delta
inhibit
inhibit
ustot
igg
alon
black
bar
figur
inhibit
mixtur
igg
ustot
igg
malian
children
rel
low
measur
strength
interfer
effect
found
interfer
effect
igg
total
igg
pool
higher
titer
greater
total
igg
pool
lower
titer
believ
higher
titer
reflect
malaria
exposur
malian
children
higher
titer
also
display
higher
titer
malaria
antigen
unpublish
observ
therefor
correl
antibodi
level
origin
total
igg
pool
strength
interfer
effect
igg
suggest
interfer
effect
due
antibodi
malaria
antigen
interfer
mechan
igg
indirect
elisa
competit
elisa
result
suggest
possibl
igg
may
bind
andor
first
may
block
abil
growthinhibitori
antibodi
bind
critic
site
complex
format
studi
requir
reveal
mechan
interfer
igg
studi
may
enhanc
understand
invasioninhibit
mechan
human
polyclon
antibodi
mixtur
experi
figur
use
igg
mgml
physiolog
concentr
igg
human
serum
mgml
previou
studi
prepar
igg
malian
adult
mgml
igg
test
howev
mgml
igg
show
clear
interfer
effect
result
suggest
certain
level
igg
need
detect
interfer
effect
assay
hand
use
igg
mgml
sever
show
inhibit
figur
difficult
calcul
interfer
effect
mixtur
show
lower
inhibit
igg
alon
therefor
decid
use
mgml
concentr
previou
studi
concentr
igg
ustot
igg
use
mixtur
experi
parasit
fvo
mgml
median
level
antibodi
malian
children
immun
mgml
therefor
reason
assum
igg
interfer
growthinhibitori
activ
igg
physiolog
ratio
ie
mix
mgml
igg
mgml
igg
studi
clearli
show
interfer
igg
year
old
children
main
target
bloodstag
vaccin
vaccin
develop
point
view
one
concern
whether
vaccin
induc
interf
igg
previou
studi
detect
interfer
effect
igg
us
vaccine
studi
suggest
vaccin
per
se
unlik
induc
interfer
igg
least
malaria
popul
studi
volum
plasma
malian
child
small
make
suffici
amount
andor
igg
experi
even
collect
larger
amount
plasma
individu
child
practic
imposs
differenti
andor
igg
induc
vaccin
induc
natur
infect
children
live
malaria
endem
area
reason
difficult
exclud
possibl
vaccin
induc
interf
igg
target
popul
howev
shown
figur
igg
children
immun
vaccin
show
less
interfer
children
without
vaccin
level
origin
total
igg
pool
therefor
evid
suggest
vaccin
induc
interf
igg
studi
rather
data
indic
interfer
antibodi
may
induc
natur
infect
vaccin
highli
polymorph
protein
obviou
polymorph
one
major
obstacl
make
broadli
effect
vaccin
inde
vaccin
administ
malaria
individu
antibodi
induc
vaccin
show
growthinhibitori
activ
homolog
strain
parasit
weaker
activ
heterolog
strain
parasit
regardless
adjuv
use
studi
investig
fvo
strain
parasit
result
demonstr
interfer
effect
occur
allel
form
howev
test
heterolog
combin
eg
mixtur
igg
ustot
igg
test
fvo
strain
parasit
igg
still
fvo
allelespecif
antibodi
prepar
confirm
elisa
gia
data
shown
difficult
interpret
result
mixtur
experi
fvo
parasit
test
tandem
purif
method
ie
total
igg
appli
onto
purif
column
fvo
column
sequenti
use
rabbit
antibodi
technic
problem
complet
deplet
fvo
allelespecif
antibodi
total
igg
data
shown
studi
could
conduct
test
crossreact
interf
antibodi
enough
volum
start
blood
materi
avail
one
major
question
malaria
vaccin
develop
assay
serv
surrog
clinic
protect
stage
immunolog
assay
proven
correl
clinic
protect
note
antibodi
induc
malaria
infect
immun
malaria
individu
show
growthinhibitori
activ
recent
clinic
challeng
trial
vaccin
malaria
popul
shown
signific
correl
vivo
parasit
multiplicationr
growthinhibitori
activ
measur
vitro
gia
vaccin
recipi
unpublish
observ
addit
epidemiolog
studi
shown
total
growthinhibitori
activ
invasioninhibit
activ
malaria
transmiss
season
significantli
associ
subsequ
malaria
risk
howev
epidemiolog
studi
shown
associ
therefor
one
may
disput
usag
assay
vaccin
develop
epidemiolog
studi
test
specif
antibodi
addit
interpret
growthinhibitori
activ
sampl
epidemiolog
studi
specif
antigen
straightforward
shown
figur
igg
separ
total
igg
pool
malian
children
show
similar
activ
igg
us
vaccine
howev
igg
ie
igg
display
level
inhibit
origin
total
igg
pool
figur
also
observ
phenomenon
previou
studi
separ
igg
malian
adult
total
igg
addit
anoth
studi
show
preincub
malian
children
total
igg
protein
reduc
growthinhibitori
activ
induc
natur
infect
even
though
total
igg
higher
level
titer
preincub
diminish
vaccineinduc
activ
almost
complet
data
indic
overal
growthinhibitori
activ
induc
natur
infect
simpli
sum
growthinhibitori
activ
individu
antibodi
preliminari
studi
show
addit
effect
growthinhibitori
activ
rabbit
antibodi
antibodi
unpublish
observ
furthermor
possibl
malaria
infect
induc
growthinhibitori
antibodi
also
interf
antibodi
human
least
case
shown
studi
difficult
prove
whether
nonaddit
andor
interfer
effect
realli
occur
vivo
whether
limit
vitro
assay
either
case
growthinhibitori
activ
antibodi
malaria
endem
area
specif
antigen
interpret
caution
howev
gia
function
assay
wide
use
vaccin
develop
growthinhibitori
activ
measur
gia
reflect
mechan
protect
vivo
result
studi
suggest
preexist
antimalaria
immun
may
modul
efficaci
vaccin
minimum
believ
extrem
import
take
find
account
evalu
immunogen
vaccin
studi
conduct
popul
expos
malaria
